Regeneron Pharmaceuticals has been in the news for many reasons. First, the firm is facing a lawsuit from shareholders with losses exceeding $100K, prompting them to contact Rosen Law Firm for information on their rights. Also troubling are questions about
Regeneron's transparency, as investors sue over Eylea pricing practices. On the other hand, the company has reported promising results for
Dupixent in treating Bullous Pemphigoid, which could have a positive impact. Several investment companies have increased their shares, including Andra AP fonden, Seizert Capital Partners, Edgestream Partners, E Fund Management, Greenwoods Asset Management, and others. However, it's worth noting that some, like Los Angeles Capital Management and Bay Colony Advisors, have sold shares. Analyst comments vary, with some identifying
Regeneron as a poor-performing large-cap stock while others name it as one of the best growth stocks.
Regeneron Pharmaceuticals REGN News Analytics from Mon, 05 Oct 2020 07:00:00 GMT to Sat, 08 Mar 2025 23:03:00 GMT -
Rating -2
- Innovation 5
- Information 7
- Rumor -5
